Mary Reumuth
Director of Finance/CFO at KALA BIO, INC.
Net worth: 173 562 $ as of 2024-06-29
Profile
Mary E.
Reumuth is currently an Independent Director at Olink Holding AB since 2022 and also serves as the Secretary, Chief Financial & Accounting Officer at KALA BIO, Inc. since 2014.
Previously, she worked as a Finance Director at Verenium Corp.
from 2007 to 2011 and as a Controller at Enobia Pharma, Inc. from 2011 to 2012.
She also held positions as an Auditor at Ernst & Young LLP and as a Manager-External Financial Reporting at Genzyme Corp.
Ms. Reumuth obtained her undergraduate degree from Texas A&M University.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
KALA BIO, INC.
0.36% | 2024-06-25 | 16,056 ( 0.36% ) | 113 837 $ | 2024-06-29 |
OLINK HOLDING AB
0.00% | 2024-02-04 | 2,344 ( 0.00% ) | 59 725 $ | 2024-06-29 |
Mary Reumuth active positions
Companies | Position | Start |
---|---|---|
KALA BIO, INC. | Director of Finance/CFO | 2014-01-31 |
OLINK HOLDING AB | Director/Board Member | 2022-04-06 |
Former positions of Mary Reumuth
Companies | Position | End |
---|---|---|
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Comptroller/Controller/Auditor | 2012-05-31 |
VERENIUM CORP | Director of Finance/CFO | 2011-02-28 |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Training of Mary Reumuth
Texas A&M University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
KALA BIO, INC. | Health Technology |
OLINK HOLDING AB | Health Technology |
Private companies | 4 |
---|---|
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
Verenium Corp.
Verenium Corp. BiotechnologyHealth Technology Verenium Corp. produces cellulosic ethanol derived from multiple biomass feedstocks. It manufactures and markets enzyme products in the fields of animal health and nutrition, grain processing, oilseed processing, oilfield services and other industrial processes such as pulp and paper and textiles. The company was founded in December 1992 and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Mary Reumuth